Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) and Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Nurix Therapeutics and Autolus Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nurix Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
| Autolus Therapeutics | 1 | 1 | 4 | 2 | 2.88 |
Nurix Therapeutics currently has a consensus price target of $34.21, suggesting a potential upside of 30.54%. Autolus Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 327.35%. Given Autolus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Nurix Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Nurix Therapeutics | -928.44% | -76.09% | -57.31% |
| Autolus Therapeutics | -238.66% | -178.66% | -49.34% |
Risk & Volatility
Nurix Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.
Valuation & Earnings
This table compares Nurix Therapeutics and Autolus Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nurix Therapeutics | $36.77 million | 73.98 | -$264.46 million | ($3.45) | -7.60 |
| Autolus Therapeutics | $117.39 million | 5.31 | -$287.53 million | ($1.06) | -2.21 |
Nurix Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
72.8% of Autolus Therapeutics shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Autolus Therapeutics beats Nurix Therapeutics on 11 of the 15 factors compared between the two stocks.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
